Errico Thomas J. purchased $49K of ECOR

Errico Thomas J. purchased 5,000 shares of electroCore, Inc. (ECOR) at $9.82 on 2026-09-14.

Original reporting
SEC EDGAR · Errico Thomas J.
Published Sep 22, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 11:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ECOR
Neutral
high confidence
Mentioned
$ECOR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ECORNeutralLow
01

Why it matters

The disclosed purchase adds a minor positive signal but is unlikely to affect ECOR's stock price in the short term.

02

Market read

Low relevance; the filing is a routine insider transaction with limited market impact.

03

What to watch

If the director is accumulating shares ahead of a pending catalyst, the purchase could gain relevance later.

Relevance 4/10Novelty 3/10Timing: filing date 2026-09-22

Background

Form 4 filings disclose insider transactions; investors monitor them for potential signals.

Company-level read

Ticker impact

$ECORNeutralHigh confidence
Context

Director Errico Thomas J. bought 5,000 shares of electroCore at $9.82 each, a $49K purchase filed on Form 4.

Expected impact

minimal or no immediate price change

Evidence & confidence

Purchase size is modest relative to float and market cap; typical insider buys of this magnitude have limited short‑term impact.

Market effects

None significant; electroCore operates in medical devices, but the trade is too small to affect sector sentiment.

None

None

Counterpoint

Even small insider buys can signal confidence; some traders may view this as a subtle bullish cue.

Key entities

  • electroCore, Inc.

    Medical device company listed on NASDAQ under ticker ECOR.

  • Errico Thomas J.

    Director of electroCore who filed the insider purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ECORMed

electroCore, Inc. (ECOR): Third quarter 2026 net sales of $9.7 million, an increase of 12% over $8.7 million in the third quarter of 2025

electroCore, Inc. (ECOR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 electroCore Announces Third Quarter 2026 Financial Results Third quarter 2026 net sales of $9.7 million, an increase of 12% over $8.7 million in the third quarter of 2025 Net loss of $1.3 million decreased 61% from prior year with Adjusted EBITDA net loss improving 6

$ECORMed

electroCore submits FDA 510(k) application for CIPN device

electroCore (NASDAQ:ECOR) submitted a 510(k) application to the FDA for its Quell device to treat chemotherapy-induced peripheral neuropathy (CIPN). The submission is based on two studies showing pain score reductions and improvements in neuropathy symptoms. FDA clearance is not guaranteed, and Quell is not currently approved for CIPN.

$ECORMed

electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)

electroCore, Inc. (ECOR) submitted a 510(k) premarket notification to the FDA seeking clearance for its Quell® device to treat chronic chemotherapy-induced peripheral neuropathy (CIPN). The submission is supported by clinical studies showing symptom improvements. If cleared, Quell would be among the first FDA-cleared devices for CIPN. The FDA review process is underway, with no guarantee of clearance.

$ECORMed

electroCore, Inc. (ECOR): Second quarter 2026 net sales of $9.5 million, an increase of 28% over $7.4 million in the second quarter 2025

electroCore, Inc. (ECOR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 electroCore Announces Second Quarter 2026 Financial Results Second quarter 2026 net sales of $9.5 million, an increase of 28% over $7.4 million in the second quarter 2025 Net loss of $3.1 million decreased 17% from prior year with Adjusted EBITDA net loss improving 2